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Does Probiotic Supplementation Improve Depression/Anxiety Outcome Measures?
Abstract
Background: Depression and anxiety continue to be a healthcare burden worldwide. Current
depression and anxiety treatments include medications and psychotherapy; however, for many
patients this is not enough. Literature has recently come out detailing the gut-brain axis and its
potential impact on mental health.
Purpose: This literature review sought to answer the question if probiotics could play a role in
the treatment of depression and anxiety. Specifically, does supplementation with a probiotic
improve clinical outcome measures of depression, anxiety, or both?
Methods: A comprehensive literature review was conducted using PubMed and Google Scholar
using the search terms probiotics, depression, and anxiety. Studies were selected based upon
meeting certain inclusion and exclusion criteria. In total eighteen studies met the inclusion
criteria and are reviewed in detail.
Conclusions: Among 24 research studies analyzed based on outcomes, 16 of them found
significant improvements in depression outcomes. In nine of fifteen studies, anxiety outcome
measures showed a significant improvement. It is important to note there a several limitations to
these studies such as a small sample size and rigorous inclusion and exclusion criteria which
make the results less generalizable to the public. Ultimately, more high-powered studies
measuring similar outcome measures are needed to sufficiently answer the question above.

Key Words: Depression, Anxiety, Probiotics
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Introduction
Depression and anxiety are common mental health disorders worldwide.1 The World
Health Organization (WHO) estimates that 3.8% of the world population is affected by
depression, and it continues to be a leading cause of disability and a significant contributor to the
overall global disease burden.1 Major depressive disorder (MDD) is defined as either depressed
mood most of the day, nearly every day, or loss of interest and pleasure in all or almost all
activities most of the day, almost every day for two consecutive weeks.2 In addition to meeting
these criteria, a positive diagnosis of MDD must include four of the following criteria:
significant weight loss or gain, insomnia or hypersomnia nearly every day, psychomotor
agitation almost every day, fatigue or loss of energy nearly every day, feeling of worthlessness or
excessive or inappropriate guilt, diminished ability to think and concentrate or both, and
recurrent thoughts of death.2 Current treatment for depression includes pharmacotherapy,
cognitive behavioral therapy, and interpersonal psychotherapy.3
Generalized anxiety disorder (GAD) is excessive anxiety and worry that occurs more
days than not for a minimum of 6 months.4 Additional GAD diagnostic criteria include difficulty
controlling worry and association with three or more symptoms: restlessness, easily fatigued,
difficulty concentrating, irritability, muscle tension, and sleep disturbance.4 Treatment for
anxiety is similar to that of depression, including pharmacotherapy and cognitive behavioral
therapy.5
There is a two-directional pathway between the gut and brain called the microbiome-gutbrain axis.6 Other terms for this axis include the gut-brain and brain-gut axes. This bidirectional
axis is mediated by trillions of microbes residing in the gut. It is believed to work through
various neural, immunologic, and humoral pathways to influence the gut and brain's functions.6,7
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Given these pathways, it is thought that the brain-gut axis can lead to diverse health conditions
such as inflammatory bowel disease, obesity, diabetes, allergies, autoimmune disease, and
cardiovascular disease.7 Studies have noted that the gut microbiome is different in patients with
depression compared to those without depression.6 This has warranted further investigation if gut
dysbiosis contributes to mental health disorders or if mental health disorders contribute to gut
dysbiosis.6
Given the prevalence of depression, anxiety, and mental health worldwide, this warrants
the question: are there any other treatment modalities that might reduce depression and anxiety
symptoms by considering the brain-gut axis? This paper will review the literature on whether
supplementation with a probiotic in adult patients with or without a diagnosis of depression,
anxiety, or both, improves clinical outcome measures of depression, anxiety, or both.
Methods
A comprehensive literature review was conducted using PubMed and Google Scholar
with the search terms "probiotics and depression" and "probiotics and anxiety." Inclusion criteria
included original research studies which were conducted in 2015 or later, probiotics given via
tablet or sachet, and primary or secondary outcome measures of depression, anxiety, or both,
including Beck Depression Inventory I or II (BDI, BDI-II), Beck Anxiety Inventory (BAI),
Montgomery-Asberg Depression Rating Scale (MADRS), Depression, Anxiety and Stress Scale
(DASS), Hospital Anxiety and Depression Scale (HADS), Hamilton Rating Scale for Depression
(HAM-D), Spielberger State-Trait Anxiety Inventory (STAI). Exclusion criteria included
research from earlier than 2014, if intervention consisted of a probiotic given via food, and any
outcome measures of depression, anxiety, or both that were not previously listed.
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Review of the Literature
Background
As mentioned in the introduction, depression and anxiety treatment can consist of
pharmacotherapy, cognitive behavioral therapy, and interpersonal psychotherapy.3,5
Pharmacotherapy consists of selective serotonin reuptake inhibitors (SSRIs), serotoninnorepinephrine reuptake inhibitors (SNRIs), atypical antidepressants, serotonin modulators,
tricyclic antidepressants, and monoamine oxidase inhibitors (MAOIs).3 SSRIs are typically firstline therapy based on their greater efficacy and tolerability, followed by SNRIs, atypical
antidepressants, and MAOIs.3 Psychotherapy is found to be superior to no pharmacotherapy or
psychotherapy at all, and no one type of psychotherapy is ideal over another in terms of
efficacy.3 Furthermore, a meta-analysis of 16 randomized trials found that those treated with
pharmacotherapy and psychotherapy had greater rates of recovery, suggesting that best outcomes
result from dual treatment.3 While these therapy modalities are effective for some patients, a
pooled analysis of 31 randomized antidepressant trials found that reduction of baseline
symptoms of ≥ 50% did not occur in 46% of patients.8 Additionally, many clinical trials for
anxiety disorders only document a response rate of 50-60% and a remission rate of 25-35%.9
Despite various treatment modalities, similar to depression, many patients with anxiety do not
have an appropriate treatment response.5,8
The brain-gut axis is a bidirectional pathway between our brain and gut microflora. It is
believed that gut microbiota can influence brain and gut activities through pathways such as the
production and expression of neurotransmitters and neurotrophic factors, modulating the enteric
sensory afferents, metabolite production, immunoregulation of mucosa, and maintaining the
integrity of the intestinal barrier and tight junctions.7 Studies have found that the gut microbiome
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of depressed patients differs from their healthy counterparts; for example, alterations in the four
main phyla, Bacteroidetes, Firmicutes, Proteobacteria, and Actinobacteria, have been found in
those diagnosed with MDD.6 The term probiotic is defined as a live microorganism that provides
a benefit to the host animal through promoting intestinal microbial balance. A probiotic can be
supplemented in the human diet via tablet, capsule, liquid, or powder (via sachet). It is believed
probiotics act on the brain-gut axis and help treat mental illnesses such as depression and anxiety
through various mechanistic roles such as anti-inflammatory effects, restoration of gut
permeability, modulation of neurotransmitters, attenuation of hypothalamic-pituitary-adrenal
(HPA) axis and epigenetic mechanisms.6
In depression, proinflammatory cytokines are the basis of neuroinflammation and can
disturb the brain's mechanisms involving behavior and emotion. Furthermore, these
proinflammatory cytokines induce depression via activation of the indoleamine 2,3 dioxygenase
(IDO) enzyme, which facilitates the breakdown of tryptophan (TRP) into kynurenine (KYN).
Elevated levels of KYN have been associated with a positive correlation to the severity of
depression. It is believed probiotics can help modulate proinflammatory cytokines, ultimately
reducing the breakdown of TRP into KYN.6
Additionally, depletion of any of the following neurotransmitters such as serotonin (5HT), dopamine (DA), noradrenaline (NE), and gamma-aminobutyric acid (GABA), contribute to
the development of neuropsychiatric disorders such as depression and anxiety. Dysregulation and
alteration in the gut microbiome have been found to impair neurotransmitter regulation.
However, various probiotic species have been found to enhance neurotransmitter activity of 5HT, DA, and GABA and downregulate monoamine-oxidase A (MAO-A), which ultimately
reduces the degradation of DA.6
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Likewise, stress activates the HPA-axis, and stress-induced gut dysbiosis further
exacerbates gut inflammation and permeability. This inflammation leads to the release of
proinflammatory cytokines, which are associated with one of the etiologies of depression. As
mentioned earlier, probiotics play a role in decreasing inflammation and normalizing gut
dysbiosis and permeability to assist with the normalization of the HPA-axis. In addition, studies
have shown that administration with a probiotic has lessened stress-induced plasma
corticosterone levels which is the main objective for normalization of the HPA-axis.6
Epigenetics is the study of how behavior and environment change the way our genes
work.10 It is believed that gut microbiota exerts epigenetic effects within the brain-gut axis via
their metabolites, such as short-chained fatty acids (SCFAs), butyrate, acetate, and propionate.
Any gut dysbiosis can negatively affect epigenetic activity and influence behavioral outcomes. 6
Probiotics have been suggested for use in gut dysbiosis to help modulate gut microbiota and
restore epigenetic changes leading to beneficial behavioral changes.6
Clinical Outcome Measures of Depression and Anxiety
There are a variety of ways to clinically measure depression and anxiety. For this
literature review, the following outcome measures are assessed and are briefly described below.
The studies are then discussed based on the outcome measure of depression, anxiety, or both, and
a final discussion and analysis of the study implications is provided.
1. Beck Depression Inventory (BDI) I and II assess the severity of depression. It consists of
21 multiple choice questions, each consisting of four answer options that range in
intensity of symptoms. Each answer is assigned a value from 0-3 and totaled at the end;
ultimately, the higher the score, the more severe the depression level.11 The BDI has been
shown to have good internal consistency and is sensitive to change. Furthermore, there
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currently isn’t any evidence the BDI I or II is more valid or reliable than other depression
scales.12
2. Beck Anxiety Inventory (BAI) assesses the severity of anxiety. Like the BDI, this
assessment consists of 21 multiple choice questions with four answer options. A score of
8-15 suggests mild anxiety, 16-25 moderate anxiety, and 26-63 severe anxiety.13
Additionally, the BAI has been found to have good validity and sensitivity to
anxiety.14(p2)
3. Montgomery-Asberg Depression Rating Scale (MADRS) is 10 area assessment survey
given by clinicians to determine the severity of depression. The ten areas are graded
based upon a score of 0-6 in severity. A score of 0-6 is absent depression symptoms, 7-19
is mild depression, 30-34 is moderate depression, and 35-60 is severe depression.15 The
MADRS is an adaptation of the HAM-D scale and found to have greater sensitivity to
change in symptoms.16
4. Depression, Anxiety and Stress Scale (DASS) consists of 42 questions divided into three
sections: anxiety, depression, and stress.17 Each unit contains 14 items, and patients rate
the severity and frequency of their symptoms over the past week.17 In addition to the 42question survey, there is a shorter DASS-21 version with only seven questions per
section, and the score is multiplied by two to and compared to DASS-42.17,18 There is
good evidence that the DASS is a reliable measure of anxiety and depression, and it is
potentially one of the best surveys for people with co-occurring anxiety and depression.19
5. Hospital Anxiety and Depression Scale (HADS) is a 14-item questionnaire divided into
two-7 item sections, including anxiety (HADS-A) and depression (HADS-D).20 The test
was created to indicate the likely presence of depression and anxiety in ill patients.21 It
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has been shown HADS is not as effective at accurately determining the presence of
depression and anxiety.21 A score of 0-7 in either area indicates normal, 8-10 is
borderline abnormal, 11-21 is abnormal.20
6. Hamilton Rating Scale for Depression (HAM-D) is a 21-item inquiry; however, only 17
are assessed. The HAM-D allows the clinician to evaluate the severity of depression. A
score of 0-7 is usually accepted to be within normal limits, and a score of 20 or higher
indicates at least moderate severity of depression.22 As stated above, the HAM-D is not as
sensitive to change over time as the MADRS.16
7. Spielberger State-Trait Anxiety Inventory (STAI) is a test to measure trait and state
anxiety.23 The test can also be used to diagnose anxiety and distinguish it from
depression. However, the test is criticized for not distinguishing between anxious and
depressive symptoms as well as other tests.19 The most common form of the STAI is
Form Y (STAI-Y). This version consists of 20 items assessing trait anxiety and 20 items
assessing state anxiety. Each question is rated on a 4-point scale from 'rarely' to 'almost
always’. A higher score is indicative of a higher level of anxiety.23
Beck Depression Inventory I and II
Seven studies measured BDI as a clinical outcome measure of depression. Akkasheh et
al24 conducted a randomized, double-blind, placebo-controlled clinical trial with 40 patients
between the ages of 20 and 55. Patients either received a probiotic capsule consisting of
Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium bifidum or a placebo capsule
for eight weeks. Participants took the BDI at the beginning and end of the study. Pertinent
inclusion criteria included a prior diagnosis of MDD and a score of ≥ 15 on the 17-item HAM-D.
Patients were excluded from the study if they were taking any dietary or probiotic supplements
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within the past two months. Akkasheh et al24 found that patients receiving probiotics had
significantly decreased BDI total score compared to placebo (p=0.001).24
The next study conducted by Miyaoka et al25 was an open-label prospective study. Like
the study done by Akkasheh et al24, it was eight weeks long and had a patient number of 40.
However, to be included in this study, patients had to be diagnosed with treatment-resistant
major depressive disorder (TRD), a HAM-D score of ≥16, and previous inadequate or
nonresponse treatment with two or more different classes of antidepressants for eight weeks. If
patients were taking an antidepressant, it was required that they be on the medication for at least
one month before the study and maintain the same dose throughout. Patients were divided into
two groups to receive the probiotic Clostridium butyricum MIYAIRI 588 or placebo. Unlike the
study done by Akkasheh et al24, the participants of this study were given a lower dose of the
probiotic during week one, and then it was increased from weeks 2-8; additionally, there was no
placebo group. BDI was taken at baseline and then at week eight. Miyaoka et al25 found no
adverse effects from the probiotic. Additionally, Miyaoka et al25 found a significantly reduced
mean BDI score at the end of the study compared to the control (p<0.001).25
Kazemi et al26 conducted a placebo-controlled, double-blind, randomized control trial
over eight weeks. However, unlike the previous two studies, this study had a larger population
size of 110. Patients were assigned to receive a probiotic containing Lactobacillus helveticus,
Bifidobacterium longum, a prebiotic containing galactooligosaccharide, or a placebo daily. Like
the previous studies, this study required a prior diagnosis of mild to moderate major depression.
Other inclusion requirements included age 18-50 years and currently taking an antidepressant
such as sertraline, fluoxetine, citalopram, or amitriptyline for three or more months before the
study start. Exclusion criteria included any probiotic supplementation within two months before
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the study and any intake of antibiotics during the study. Participants took the BDI at baseline and
the end of the study. Only 73.6% of patients finished the trial. Kazemi et al26 found there was a
significant decrease in the BDI score of the probiotic group compared to the placebo (p=0.042). 26
Chahwan et al27 conducted a triple-blinded parallel, placebo-controlled randomized
clinical trial of 71 patients. The patients received either two sachets daily of probiotic containing
Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium lactis W52,
Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56,
Lactobacillus salivarius W24, Lactobacillus casei W56, Lactobacillus salivarius W24,
Lactococcus lactis W19, and Lactococcus lactis W58, or a placebo sachet for eight weeks. To be
included in the study, patients needed to have a BDI-II score of ≥ 12, be 18 years or older, and
take no medications. Unlike the previous studies, Chahwan et al27 noted a reduction in symptoms
of both the probiotic and placebo group, which was not statistically different from each other.
This study had potential bias due to the author being an employee of Winclove probiotics.27
Moludi et al28 conducted a randomized, double-blind study of 96 patients over eight
weeks. Unlike the previous studies, it consisted of four arms: placebo, probiotic alone containing
Lactobacillus rhamnosus G, prebiotic inulin, or probiotic plus prebiotic. Additionally, unlike the
previous studies, patients had to have a diagnosis of coronary artery disease (CAD) to be
included. Exclusion criteria consisted of a history of prebiotic and probiotic use within the past
two months. Participants took the BDI-II at baseline and end of the study. Moludi et al28 found
that the BDI score of the probiotic group significantly decreased (p=0.001) compared to baseline.
Additionally, the probiotic and prebiotic co-supplementation group had significant drops in the
BDI score (p=0.001) compared to the placebo group. 28
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The subsequent study is a randomized, double-blind, placebo-controlled study of 60
patients over 12 weeks. Ostadmohammadi et al29 sought to determine the effects of vitamin D
and probiotic co-administration on mental health, hormones, and inflammatory and oxidative
stress in women with polycystic ovarian syndrome (PCOS). Patients either received 50,000 IU of
vitamin D every two weeks plus a probiotic capsule daily containing Lactobacillus acidophilus,
Bifidobacterium bifidum, Lactobacillus reuteri, and Lactobacillus fermentum, or a placebo
containing corn oil and starch. To be included in the study, patients must have a diagnosis of
PCOS, body mass index (BMI) of 17-34, insulin resistance in the range of 1.4-4, and age 18-40
years. Patients were excluded from the study if they had any other psychological or psychiatric
comorbidities such as anxiety or depression at the time of enrollment. Participants took the BDIII at baseline and end of the study. Ostadmohammadi et al29 found no side effects from taking
vitamin D and a probiotic, and at 12 weeks, the vitamin D and probiotic group saw an improved
BDI score compared to the placebo (p=0.04).29
Ho et al30 conducted the final study that used BDI as an objective outcome measure and
is a randomized, double-blind, parallel, placebo-controlled pilot trial of 40 patients over 30 days.
One group received the probiotic PS128, and the other received the placebo. Pertinent inclusion
criteria included those aged 20-40 years, having a BMI of 18.5-25, and having a blood pressure
of <140/90. The study excluded patients if they used probiotics within the past two weeks and
antibiotics within the last month or both. Participants took the BDI-II at baseline, day 15, and
day 30 of the study. Ho et al30 found there were no harmful events from taking the probiotic
capsules. The compliance rate of the study was high at 98%. This study found that the BDI-II
scores of the probiotic group decreased significantly from baseline to day 30 (p=<0.05).
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Additionally, compared to the control, the probiotic group showed a significant reduction in
BDI-II scores.30
When taking into consideration the above studies, which used BDI as a measurable
outcome of depression, all the studies but one found a statistically significant improvement in
BDI score compared to placebo/control when supplemented with a probiotic. The one study
which did not find a statistically significant difference between the probiotic and placebo group
saw an equal improvement in the BDI scores, suggesting probiotics still have a beneficial impact
on depression. However, despite these positive findings, it is essential to note that the studies had
small sample sizes and very restrictive inclusion and exclusion criteria. Two of the studies
focused on specific populations, which included CAD and PCOS, making their findings less
generalizable to the public. Four studies included criteria requiring a certain level of depression,
but the three other studies showed similar results. Lastly, a few of the studies didn't test probiotic
supplementation alone, but in adjunct with vitamin D, prebiotic, and antidepressants which bodes
the question if the adjunct therapy played more of a role than the probiotic?
Montgomery-Asberg Depression Rating Scale
In total, three studies measured MADRS as a clinical outcome measure of depression.
Romijen et al31 conducted a double-blind, randomized, placebo-controlled trial for eight weeks
with 79 patients. It sought to answer the question if probiotics improved mood, stress, and
anxiety in those who had low mood already. Patients either received a probiotic sachet
containing Lactobacillus helveticus R0052 and Bifidobacterium longum R0175, or a placebo
sachet. Pertinent inclusion criteria included a Quick Inventory of Depressive Symptomatology
(QIDS-SR16) of ≥ 11 or a score on the depression subscale of the DASS of ≥ 14 and being free
of any psychiatric medication for at least four weeks before the trial. Patients were excluded
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from the trial if they used any supplement considered to be an antidepressant potentially and if
they had current or recent use of a probiotic or antibiotic. Participants took the MADRS at
baseline and week eight, and a response was >60% reduction in score from baseline. This study
found there wasn't a statistically significant difference in the decrease between the probiotic and
placebo group (p=0.62).31
Majeed et al32 sought to answer the question, what is the safety and efficacy of
supplementing probiotics for MDD in patients with irritable bowel syndrome (IBS). This study
was a randomized, multi-center, double-blind, placebo-controlled, parallel clinical trial
consisting of 40 patients over 90 days. Patients received either a probiotic containing Bacillus
coagulans MTCC 5856 or a placebo tablet. To be included in the study, patients must have a
diagnosis of IBS for the past three months with symptom onset at least six months before
diagnosis, a diagnosis of MDD, and could not use any medication or be on any supplement or
antibiotic one month before study start. Exclusion criteria consisted of those who had a past
psychiatric diagnosis. Majeed et al32 found that by day 90, there was a statistically significant
difference between the decrease in probiotic and placebo scores (p=0.007). It is of note that one
author was an employee of the company that produced the probiotic for the trial, which leads to
potential bias.32
Wallace and Milev33 conducted an 8-week open-label pilot study of 10 patients. The
patients consumed a probiotic supplement containing Lactobacillus helveticus R0052 and
Bifidobacterium longum R0175 via sachet once daily. Participants took the MADRS at baseline,
weeks 4 and 8. For participants to be part of the study, they had to be 18-65 years, currently
diagnosed with an episode of MDD, and not taking any antidepressant medication. Pertinent
exclusion criteria included any use of antidepressants, use of antibiotics within the past four
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weeks, daily use of probiotics within the last two weeks, and consumption of any fortified
probiotic foods. Wallace and Milev33 found there was a significant reduction in mean MADRS
score between baseline and week 4 (p<0.001), but there was no significant difference between
weeks 4 and 8 (p=0.377). Additionally, there were no adverse effects from the probiotic. 33
In total, three studies measured MADRS as an outcome measure of depression. All the
studies had small sample sizes, and one study had no control/placebo group for comparison. All
three studies required a prior diagnosis or a certain threshold of depression for study admission.
One study focused on a specific population of IBS patients, which makes the results less
generalizable compared to the other studies. All three studies were similar in not allowing
antidepressant medication and prior antibiotic treatment. Romijen et al31 did not have significant
results; however, they discussed their patient population was highly treatment-resistant, which
could be a limiting factor in their results.
Hamilton Rating Scale for Depression
In total, three studies measured HAM-D as a clinical outcome measure of depression and
anxiety. Rudzki et al34 conducted an eight-week, double-blind, placebo-controlled study on 79
patients. Patients consumed either an SSRI and probiotic containing Lactobacillus plantarum
299v or an SSRI and placebo. Pertinent inclusion criteria include a diagnosis of MDD and either
already on SSRI monotherapy or drug-free upon admission to study and started on an SSRI.
Relevant exclusion criteria include current treatment with antipsychotics, mood stabilizers,
antibiotics, glucocorticosteroids, or both. The primary outcome measure was HAM-D taken at
baseline, weeks 4 and 8. Rudzki et al34 found no significant side effects in the probiotic and
placebo groups. Additionally, there was no statistically significant difference of the HAM-D
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score between the placebo and probiotic groups (p=0.205). Despite this negative finding, there is
a lack of adequate discussion of the results in the study's discussion section. 34
The following two studies by, Majeed et al32 and Miyaoka et al25, were reviewed in detail
in previous sections. Majeed et al32 found that by day 90, there was a significant difference
between the placebo and probiotic group in the primary outcome HAM-D score (p=0.005).32
Miyaoka et al25 found the probiotic supplemented group had a significantly reduced mean HAMD score (p<0.001), and 70% of patients had a reduction in HAM-D score of >50%.25
When comparing the following studies, all three had small sample sizes, which makes
their results less generalizable to the public. Rudzki et al34 only had 75.9% of the participants
complete the study, which further decreases an already small sample size. All three studies
required some level of MDD to participate in the study, which makes their results more
comparable; however, three different strains of probiotics were tested. Majeed et al32 required a
specific diagnosis of IBS in addition to MDD, which further decreases the study's
generalizability. Miyaoka et al25 did not require a placebo-control group and therefore had no
adequate comparison to test the efficacy of the probiotic. Majeed et al32 had potential bias due to
the authors of the study being employees of Sabinsa Corporation/Sami Labs Limited, which
manufactures and markets LactoSpore. In total, two of the three studies had positive findings in
terms of probiotics improving HAM-D scores.
Depression, Anxiety, and Stress Scale
In total, six studies measured DASS as a clinical outcome measure of depression, anxiety,
or both. Mohammadi et al35 conducted a double-blind, placebo-controlled trial of 75 patients
over six weeks. The study aimed to determine the effects of probiotic yogurt and multispecies
probiotic capsule on mental health and the HPA axis in petrochemical workers. Patients were
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either given a probiotic yogurt plus placebo capsule, a probiotic capsule containing Actobacillus
casei, Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus bulgaricus,
Bifidobacterium breve, Bifidobacterium longum, S. thermophilus, or conventional yogurt plus a
placebo capsule. The DASS was measured at the start and end of the study. To be included,
patients had to be petrochemical workers aged 20-60 years. Exclusion criteria included those
taking vitamin supplements, antibiotics, or any other form of nutritional supplement.
Mohammadi et al35 found DASS score improvement in the probiotic yogurt (p=0.02), probiotic
capsule group (p=0.006), and no significant improvement in the conventional yogurt plus
placebo group (p=0.08).35
The next study is an eight-week, randomized, double-blind, placebo-controlled study of
60 overweight or obese adults. Patients received either a placebo capsule or a symbiotic capsule
containing Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, and inulin.
Participants took the DASS-21 at baseline and end of the study. Inclusion criteria included those
aged 20-50 years with BMI greater than 25 and less than 35. Exclusion criteria included those on
antidepressant drugs, prebiotics, and probiotic supplements. Hadi et al36 found a significant
improvement in DASS anxiety score (p=0.03) and DASS depression score (p=0.03) compared to
placebo.36
Chong et al37 conducted a randomized, double-blind, placebo-controlled trial of 111
patients over 12 weeks. Patients consumed either a sachet containing Lactobacillus plantarum
D37 or a placebo sachet daily. Participants took the DASS at baseline, weeks 4, 8, and 12.
Inclusion criteria included those aged 18-60 years with moderate stress levels on Cohen's
Perceived Stress Scale (PSS-10). No pertinent exclusion criteria were noted for this study. The
study found that for anxiety, the DASS scores improved in all populations, and after eight weeks,
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there was a higher reduction of total DASS anxiety scores observed as compared to the placebo
(p=0.017). Nevertheless, there was no difference in the DASS depression score of the probiotic
group compared to the placebo.37
This paper discussed the details of the following three studies earlier in the article. Please
reference above for more information. Ostadmohammadi et al29 found at 12 weeks, the group
supplemented with vitamin D, and a probiotic saw improved DASS scores compared to the
placebo (p=0.02).29 Chahwan et al27 found no significant difference between the probiotic
supplemented group and placebo for DASS; however, both groups reduced overall symptoms. 27
Romijen et al31 found no significant difference in DASS score for depression (p=0.99) or anxiety
(p=0.78) when supplemented with probiotics.31
When comparing the above studies, a significant strength of all the studies was that they
were blinded, randomized, and placebo controlled. However, a weakness of all the studies was
that they had small sample sizes, which made their results less generalizable. Three studies found
no improvement in DASS depression, anxiety or both compared to placebo – two of these studies
required a certain level of depression to enter the trial, and one study required a certain stress
level. The study conducted by Chahwan et al27, had potential bias due to an author working for
Winclove probiotics in addition to an attrition rate of 34%. Several studies which did find an
improvement in DASS depression, anxiety, or both scored required specific patient populations,
including either being a petrochemical worker or having a diagnosis of PCOS, which makes their
results less generalizable. All studies used different types of probiotics which bodes the question,
does one probiotic have better results if further tested?
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Hospital Anxiety and Depression Scale
In total, three studies measured HADS as a clinical outcome measure of depression,
anxiety, or both. Haghighat et al38 led a 12-week randomized, double-blinded, placebo-controlled
trial of 75 patients. Patients received either a symbiotic containing prebiotic and probiotic
Lactobacillus acidophilus, Bifidobacterium bifidum BIA-6, Bifidobacterium lactis BIA-7 and
Bifidobacterium ongum BIA-8, a probiotic alone containing the above, or a placebo. HADS was
measured at baseline and at the end of the study. Pertinent inclusion criteria included being
clinically stable on hemodialysis (HD) with an arteriovenous fistula. Exclusion criteria included
any prebiotic, probiotic supplement or food, antibiotics, or both within the past month.
Haghighat et al38 found there were no adverse events related to supplement intake. In the
symbiotic group, there was a significant drop in HADS depression score (p=0.009) from baseline
to week 12, but not for HADS anxiety (p=0.47). For the probiotic group, there was a significant
drop in HADS depression score (p=0.041) from baseline to week 12, but not for HADS anxiety
(p=0.661). There was no significant difference in scores from baseline to week 12 for both
HADS depression and anxiety in the placebo group (p=0.10, p=0.84). When compared, there
was a significant difference between the three groups for the HADS depression score (p=0.003)
but not for HADS anxiety (p=0.58).38
Smith-Ryan et al39 conducted a 6-week double-blind, randomized, placebo-controlled
study of 42 patients. Patients either received two placebo sachets or two sachets one of a
probiotic containing Bifidobacterium bifidum W23, Bifidobacterium lactis W51, Bifidobacterium
lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56,
Lactobacillus salivarius W24, and Lactococcus lactis W19 and W58 and the other a prebiotic
containing resistant maize starch W117. HADS was taken at the start and end of the study. Only
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33 patients finished the study and were used for statistical analysis. Smith-Ryan et al39 found no
statistically significant difference in changes for HADS anxiety (p=0.621) or HADS depression
(p=0.506) in the symbiotic group. Additionally, there were no clinically significant results for the
decrease in HADS anxiety score for the symbiotic group compared to the placebo group, but
there was a clinically relevant decrease in the score of the symbiotic group. 39
Pinto-Sanchez et al40 performed a 10-week randomized, double-blind, placebo-controlled
study of 44 patients. Patients either received a probiotic sachet containing Bifidobacterium
longum NCC3001 or a placebo. Pertinent inclusion criteria include a diagnosis of IBS based
upon Rome III criteria, mild to moderate anxiety, depression or both. Applicable exclusion
criteria included any other psychiatric condition besides depression, anxiety, or both and the use
of antidepressants. Pinto-Sanchez et al40 found that at six weeks, there was a statistically
significant decrease in HADS depression scores of 78% in the probiotic group compared to 35%
in the placebo group (p=0.016). At the ten-week follow-up, this significant difference was
sustained (p=0.04). There was no significant difference in the number of patients with decreased
anxiety at six weeks (p=0.19) and ten weeks (p=0.34).40
A major strength of all studies using HADS as a primary or secondary outcome measure
was that they were all randomized, double-blind, placebo-controlled studies. However, a major
limitation of all these studies is the small sample size which decreases the generalizability of the
results. There is a further decrease in the generalizability of the three studies due to them
focusing on specific patient populations such as female shift workers, hemodialysis patients, and
prior diagnoses of IBS. Two studies saw positive outcomes in depression scores compared to
placebo, but only one of these studies required a previous diagnosis of depression and anxiety,
while the other tested a symbiotic vs. probiotic alone. One study that didn't see an improvement
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in depression scores had potential selection bias due to the population being more healthconscious. This same study had difficulty recruiting participants, and most patients were young.
There was no improvement in HADS anxiety score for any study, suggesting probiotics are more
beneficial in treating depression when HADS is the outcome measure.
Beck Anxiety Inventory
In total, four studies measured BAI as a clinical outcome measure of anxiety.
Eskandarzadeh et al41 conducted a double-blind, randomized, placebo-controlled study of 48
patients over eight weeks. Patients were given either a probiotic capsule plus sertraline or
placebo plus sertraline. Pertinent inclusion criteria included a prior diagnosis of GAD.
Applicable exclusion criteria included taking any other medications or supplements during the
intervention. Eskandarzadeh et al41 observed that at eight weeks, there was a greater reduction in
the BAI score of the probiotic group compared to the placebo; however, this difference was not
statistically significant (p=0.25).41
The following three studies have been reviewed in more detail earlier in the paper for
reference. Miyaoka et al25 measured BAI as a secondary outcome. They learned there was a
significant reduction in the mean BAI score for the probiotic group (p<0.001).25 Ho et al30 found
there was a significant decrease in BAI score from baseline to day 30 in the probiotic group
(p=<0.05). However, when the probiotic group was compared to the placebo group, there was no
statistically significant difference.30 Lastly, Chahwan et al27 discovered there was no significant
difference between the probiotic group and control group for BAI.27
When considering these four studies, three were stronger because they were double or
triple-blinded, randomized, and placebo controlled. All the studies were limited by their small
population size; thus, their results are not as generalizable to the public. Two of the studies found
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a significant reduction in mean BAI score; however, compared to placebo, it wasn't significantly
different. An additional study found a significant reduction in the mean BAI score but failed to
compare it adequately to the placebo group. This same study had potential bias due to inadequate
participant blinding. All four studies varied in their inclusion criteria which did not seem to
influence the overall results.
Spielberger State-Trait Anxiety Inventory
In total, three studies measured STAI as a clinical outcome measure of anxiety. All three
studies have been reviewed previously in the paper for reference. Moludi et al28 observed STAI
score significantly decreased in the probiotic supplemented group compared to baseline results
(p=0.006). This same study found adding prebiotics to the probiotic amplified the improvement
outcomes than prebiotics or probiotics alone. Lastly, this study found probiotic and prebiotic cosupplementation resulted in a significant drop in STAI score compared to placebo (p=0.020). 28
Wallace and Milev33 noticed a significant reduction in mean STAI score from baseline to week 4
(p=0.016), but not from week 4 to week 8 (p=1.000). 33 Eskandarzadeh et al41 found that at week
eight there was a greater STAI score in the probiotic group than the placebo; however, there was
no statistically significant difference between the group scores.36
Two of the three above studies were stronger because they were randomized, doubleblind, placebo-controlled studies. Each study had a small sample size which makes the results
less generalizable. Each study had unique inclusion criteria, such as a prior diagnosis of MDD,
GAD, or CAD. One of two studies that found a significant reduction in mean STAI score from
baseline to week four was severely limited due to patients being unblinded and lack of control or
placebo group, which left the study liable to confirmation bias on both sides. Additionally, this
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same study had a population sample skewed to young adult females, which further decreases its
generalizability.
Discussion/Analysis
Depression and anxiety continue to be major health concerns all over the world. Current
treatment modalities include psychotherapy and medications. Despite these modalities being
successful for some individuals, many continue to have TRD and would benefit from other
treatment modalities. Research has come out regarding the gut-brain axis and its potential role in
mood, which has led to the question, would supplementation with probiotics in adult patients
with or without a diagnosis of depression, anxiety, or both improve clinical outcome measures of
depression and anxiety? This literature review reviewed 18 original research studies and will
analyze seven depression and anxiety outcome measures, including BDI, MADRS, DASS,
HAM-D, HADS, BAI, and STAI.
Supplemented probiotics appear to have a better effect on improving depression outcome
scores than anxiety. For example, six out of the seven studies which measured BDI as an
outcome measure of depression observed a statistically significant improvement in BDI score
compared to placebo. Similarly, two out of three studies that measured MADRS, HAM-D, and
HADS as an outcome measure of depression found a statistically significant improvement in
depression scores. However, only three out of six studies that used DASS as an outcome measure
saw statistically significant improvement in DASS scores. It is possible the studies measuring
DASS did not have as positive results for depression due to the test not being as accurate at
measuring depression alone versus in combination with anxiety. While these findings appear
promising, it is important to acknowledge a major limitation of these is the lack of adequate
sample size and, therefore, lack of generalizability to the public.
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In addition, no study tested the same formulary of probiotics, which weakened the
findings. There was a common use of Lactobacillus acidophilus, Bifidobacterium bifidum, and
Bifidobacterium longum. Further studies of these three probiotic strains are warranted.
Furthermore, some studies used adjunct therapies such as vitamin D or antidepressants, making it
hard to determine whether probiotics alone contribute to depression outcomes or whether they
are just a beneficial addition. A great example of all these factors is the study conducted by
Kazemi et al26, which was of 110 patients with a prior diagnosis of MDD. Kazemi et al26
uncovered a significant decrease in the BDI score of the probiotic group compared to the
placebo; however, this study notes several important limitations, such as participants on various
types of antidepressants and lack of appropriate gut microbiota measurement.
In comparison to the results on depression, anxiety showed slightly less favorable results.
For the studies that either measured DASS score overall or specifically the DASS anxiety subset,
four out of five studies found statistically significant improvement in DASS overall or DASS
anxiety subset. For the studies using BAI as an outcome measure, three out of four studies noted
a significant score improvement; however, one of these studies didn't have a control group for
comparison, and the other two did not find a statistically significant difference between the
probiotic and placebo group. The next measurement of anxiety was STAI-Y which two out of
three studies saw statistically significant improvement in the anxiety score. Lastly, the three
studies which measured HADS as an outcome measure did not find any statistically relevant
data. It is possible the studies using HADS had poorer outcomes due to the fact HADS is meant
to test for the likelihood of depression and anxiety, not necessarily the severity. When taking into
consideration the tests which are strong at measuring anxiety, eight out of eleven studies showed
improvement in anxiety measurements.
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Like the studies which measured depression outcomes, the studies measuring anxiety
outcomes were underpopulated, and therefore their results are less generalizable to society. The
studies also measured various strains of probiotics, sometimes in conjunction with other
medications or supplements, which further weakens the significance of the results. A great
example study is the one conducted by Haghighat et al38. This study focused on a specific subset
population of 75 hemodialysis patients; while there was an improvement in the HADS
depression score, there was no improvement in the HADS anxiety score for probiotic or
symbiotic.
Given all the above information regarding the studies of probiotics on depression and
anxiety outcome measures, it remains difficult to conclude if supplementing with a probiotic will
improve depression and anxiety outcomes. While findings have varied, even in those studies
which have positive results, there remain severe limitations to the studies, such as small sample
size and specific inclusion criteria, which decrease the generalizability of the study.
Nevertheless, from these findings, it can be concluded there are minimum side effects, if any, to
supplementing with probiotics. This evidence suggests that although it may not show a benefit in
everyone, it is safe to try supplementing probiotics to see if it improves symptoms of depression
and anxiety.
Conclusion
This literature review sought to answer the question: does supplementation with a
probiotic improve clinical outcome scores of depression, anxiety or both in adults with or
without a diagnosis of depression, anxiety, or both. Overall, probiotic supplementation improved
depression outcome measures more than anxiety outcomes. However, despite more positive
outcomes for patients with depression, there are still severe limitations to the studies, including
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small sample size, different probiotics or combinations of probiotics used, adjunctive treatment
such as vitamin D, strict inclusion, exclusion criteria, or both. This paper cannot undoubtedly
state that probiotic supplementation improves clinical outcome measures of depression and
anxiety; however, no significant adverse effects were noted, and supplementation remains safe.
Overall, more high-powered studies using consistent probiotic strains and outcome measures is
warranted to better answer the question above. Ultimately, it is the decision between the provider
and patient whether attempting to lessen the symptoms of depression and anxiety with
supplemented probiotics is beneficial.
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